MYC and cancer: Patients with MYC gain or PTEN loss or both alterations at biopsy tended to have higher maximum percentage of tumor involvement on any biopsy core (P = 0.0007), but molecular findings were not significantly associated with patient age, race, preoperative PSA level, clinical stage, fraction of biopsy cores involved by cancer or presence of bilateral disease on biopsy, or percentage of Gleason pattern 4 carcinoma (Table 2).